Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization

Abstract Background To confirm the prognostic value of previously published baseline interleukin 6 (IL6) and IL8 cutoff values in survival and liver dysfunction in patients with advanced HCC undergoing 90Y radioembolization. Methods A total of 83 patients (77 male) represented a subset of HCC patien...

Full description

Bibliographic Details
Main Authors: Osman Öcal, Juozas Kupčinskas, Egidijus Morkunas, Holger Amthauer, Kerstin Schütte, Peter Malfertheiner, Heinz Josef Klümpen, Christian Sengel, Julia Benckert, Ricarda Seidensticker, Bruno Sangro, Moritz Wildgruber, Maciej Pech, Peter Bartenstein, Jens Ricke, Max Seidensticker
Format: Article
Language:English
Published: SpringerOpen 2021-06-01
Series:EJNMMI Research
Subjects:
Online Access:https://doi.org/10.1186/s13550-021-00791-w
id doaj-b832054cf65348e4be321b5fb11a5a14
record_format Article
spelling doaj-b832054cf65348e4be321b5fb11a5a142021-06-06T11:26:01ZengSpringerOpenEJNMMI Research2191-219X2021-06-0111111010.1186/s13550-021-00791-wPrognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolizationOsman Öcal0Juozas Kupčinskas1Egidijus Morkunas2Holger Amthauer3Kerstin Schütte4Peter Malfertheiner5Heinz Josef Klümpen6Christian Sengel7Julia Benckert8Ricarda Seidensticker9Bruno Sangro10Moritz Wildgruber11Maciej Pech12Peter Bartenstein13Jens Ricke14Max Seidensticker15Department of Radiology, University Hospital, LMU MunichInstitute for Digestive Research and Department of Gastroenterology, Medical Academy, Lithuanian University of Health SciencesInstitute for Digestive Research and Department of Gastroenterology, Medical Academy, Lithuanian University of Health SciencesDepartment of Nuclear Medicine, Charité-Universitätsmedizin BerlinDepartment of Internal Medicine and Gastroenterology, Niels-Stensen-Kliniken MarienhospitalDepartment of Internal Medicine II, University Hospital, LMU MunichDepartment of Medical Oncology, Amsterdam University Medical Centers, University of AmsterdamRadiology Department, Grenoble University HospitalDepartment of Hepatology and Gastroenterology, Charité – Universitätsmedizin BerlinDepartment of Radiology, University Hospital, LMU MunichLiver Unit, Clínica Universidad de NavarraDepartment of Radiology, University Hospital, LMU MunichDepartments of Radiology and Nuclear Medicine, University of MagdeburgDepartment of Nuclear Medicine, University Hospital, LMU MunichDepartment of Radiology, University Hospital, LMU MunichDepartment of Radiology, University Hospital, LMU MunichAbstract Background To confirm the prognostic value of previously published baseline interleukin 6 (IL6) and IL8 cutoff values in survival and liver dysfunction in patients with advanced HCC undergoing 90Y radioembolization. Methods A total of 83 patients (77 male) represented a subset of HCC patients undergoing 90Y radioembolization combined with sorafenib as part of the prospective multicenter phase II trial SORAMIC. IL6 and IL8 levels were determined in serum samples collected at baseline. In this post hoc analysis, we sought to confirm the prognostic value of baseline cutoff values of 6.53 pg/mL and 60.8 pg/mL for IL6 and IL8, respectively, in overall survival (OS) or liver dysfunction (grade 2 bilirubin increase) after treatment. Results Median OS was 12.0 months. While low baseline albumin and high bilirubin values were associated with high IL6, liver cirrhosis, alcoholic liver disease, and portal vein infiltration were associated with high IL8. In univariate analysis, high baseline IL6 and IL8 were associated with significantly shorter overall survival (7.8 vs. 19.0 months for IL6 and 8.4 vs. 16.0 months for IL8). In addition to IL values, liver cirrhosis, Child–Pugh grade, baseline albumin (< 36 g/dL), and total bilirubin (≥ 17 µmol/L), and higher mALBI grade (2b &3) values were associated with OS. At multivariate analysis, high baseline IL6 was the only independent prognostic factor for OS (HR 2.35 [1.35–4.1], p = 0.002). Risk factors for liver dysfunction were high baseline IL6, albumin, and total bilirubin, and mALBI grade as found in univariate analysis. High baseline IL6 (HR 2.67 [1.21–5.94], p = 0.016) and total bilirubin ≥ 17 µmol/L (HR 3.73 [1.72–8.06], p < 0.001) were independently associated with liver dysfunction. Conclusion In advanced HCC patients receiving 90Y radioembolization combined with sorafenib, baseline IL6 values proved to be prognostic, confirming previous findings in patients undergoing 90Yradioembolization. IL6 might be useful for patient selection or stratification in future trials.https://doi.org/10.1186/s13550-021-00791-wHepatocellular carcinomaRadioembolizationInterleukinSurvivalLiver decompensation
collection DOAJ
language English
format Article
sources DOAJ
author Osman Öcal
Juozas Kupčinskas
Egidijus Morkunas
Holger Amthauer
Kerstin Schütte
Peter Malfertheiner
Heinz Josef Klümpen
Christian Sengel
Julia Benckert
Ricarda Seidensticker
Bruno Sangro
Moritz Wildgruber
Maciej Pech
Peter Bartenstein
Jens Ricke
Max Seidensticker
spellingShingle Osman Öcal
Juozas Kupčinskas
Egidijus Morkunas
Holger Amthauer
Kerstin Schütte
Peter Malfertheiner
Heinz Josef Klümpen
Christian Sengel
Julia Benckert
Ricarda Seidensticker
Bruno Sangro
Moritz Wildgruber
Maciej Pech
Peter Bartenstein
Jens Ricke
Max Seidensticker
Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization
EJNMMI Research
Hepatocellular carcinoma
Radioembolization
Interleukin
Survival
Liver decompensation
author_facet Osman Öcal
Juozas Kupčinskas
Egidijus Morkunas
Holger Amthauer
Kerstin Schütte
Peter Malfertheiner
Heinz Josef Klümpen
Christian Sengel
Julia Benckert
Ricarda Seidensticker
Bruno Sangro
Moritz Wildgruber
Maciej Pech
Peter Bartenstein
Jens Ricke
Max Seidensticker
author_sort Osman Öcal
title Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization
title_short Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization
title_full Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization
title_fullStr Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization
title_full_unstemmed Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization
title_sort prognostic value of baseline interleukin 6 levels in liver decompensation and survival in hcc patients undergoing radioembolization
publisher SpringerOpen
series EJNMMI Research
issn 2191-219X
publishDate 2021-06-01
description Abstract Background To confirm the prognostic value of previously published baseline interleukin 6 (IL6) and IL8 cutoff values in survival and liver dysfunction in patients with advanced HCC undergoing 90Y radioembolization. Methods A total of 83 patients (77 male) represented a subset of HCC patients undergoing 90Y radioembolization combined with sorafenib as part of the prospective multicenter phase II trial SORAMIC. IL6 and IL8 levels were determined in serum samples collected at baseline. In this post hoc analysis, we sought to confirm the prognostic value of baseline cutoff values of 6.53 pg/mL and 60.8 pg/mL for IL6 and IL8, respectively, in overall survival (OS) or liver dysfunction (grade 2 bilirubin increase) after treatment. Results Median OS was 12.0 months. While low baseline albumin and high bilirubin values were associated with high IL6, liver cirrhosis, alcoholic liver disease, and portal vein infiltration were associated with high IL8. In univariate analysis, high baseline IL6 and IL8 were associated with significantly shorter overall survival (7.8 vs. 19.0 months for IL6 and 8.4 vs. 16.0 months for IL8). In addition to IL values, liver cirrhosis, Child–Pugh grade, baseline albumin (< 36 g/dL), and total bilirubin (≥ 17 µmol/L), and higher mALBI grade (2b &3) values were associated with OS. At multivariate analysis, high baseline IL6 was the only independent prognostic factor for OS (HR 2.35 [1.35–4.1], p = 0.002). Risk factors for liver dysfunction were high baseline IL6, albumin, and total bilirubin, and mALBI grade as found in univariate analysis. High baseline IL6 (HR 2.67 [1.21–5.94], p = 0.016) and total bilirubin ≥ 17 µmol/L (HR 3.73 [1.72–8.06], p < 0.001) were independently associated with liver dysfunction. Conclusion In advanced HCC patients receiving 90Y radioembolization combined with sorafenib, baseline IL6 values proved to be prognostic, confirming previous findings in patients undergoing 90Yradioembolization. IL6 might be useful for patient selection or stratification in future trials.
topic Hepatocellular carcinoma
Radioembolization
Interleukin
Survival
Liver decompensation
url https://doi.org/10.1186/s13550-021-00791-w
work_keys_str_mv AT osmanocal prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT juozaskupcinskas prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT egidijusmorkunas prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT holgeramthauer prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT kerstinschutte prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT petermalfertheiner prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT heinzjosefklumpen prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT christiansengel prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT juliabenckert prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT ricardaseidensticker prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT brunosangro prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT moritzwildgruber prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT maciejpech prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT peterbartenstein prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT jensricke prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
AT maxseidensticker prognosticvalueofbaselineinterleukin6levelsinliverdecompensationandsurvivalinhccpatientsundergoingradioembolization
_version_ 1721394119793704960